Leading the Way in Life Science Technologies

GEN Exclusives

More »

Best of the Web

More »
Feb 01, 2005 (Vol. 25, No. 3)

Electronic Frontier Foundation's patent Busting Project

URL:www.eff.org/patent
  • Important topic
  • A bit one-sided
Biotechnology is a patent-intensive industry, supported strongly by the system which encourages research with the reward of protection for an invention for up to 20 years. That’s all fine and dandy on paper, but in practice, the issuing of patents is anything but a science (or even consistent). As noted on the opening page of this rather aggressive site, nothing less than the Federal Trade Commission is getting in the act to find a proper balance between innovation and patent law/policy. There is considerable concern in the areas of computing and software development, for example, that frivolous or improperly issued patents may significantly stifle the next generation of computing. Yikes! Now that’s serious.
  • Key:
  • Strong Points
  • Weak Points
  • Ratings:
  • Excellent
  • Very Good
  • Good


*The opinions expressed are solely those of the author(s) and should not be construed as reflecting the viewpoints of the publisher, Genetic Engineering & Biotechnology News, Mary Ann Liebert, Inc., the publishing house, or employees and affiliates thereof.

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »